 MONMOUTH JUNCTION, N.J., Oct. 12, 2021 PRNewswire -- CytoSorbents Corporation NASDAQ: CTSO, a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the full approval of its Investigational Device Exemption IDE application by the FDA to conduct the pivotal STARD Safe and Timely Antithrombotic Removal Direct Oral Anticoagulants DOAC double-blind, randomized, controlled trial in the United States to support FDA marketing approval. 